Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — Merger or Acquisition (August 2015)
14 slides from Emergent Biosolutions's merger presentation, Aug 6, 2015
Slide 1: Biosciences Spin-Off
Biosciences Spin-OffAugust 6, 2015 Daniel J. Abdun-NabiPresident and CEO
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding our financial guidance, statements r
Slide 3: Plan to Spin-off Biosciences Business
3 Plan to Spin-off Biosciences Business Overview Description Board of Directors has authorized management to pursue a tax-free spin-off of the company’s Biosciences business into a separate, stand-alone publicly-traded company (SpinCo) Outcome Separation is expected to create two independent public
Slide 4: Compelling For Both Companies & Shareholders
4 Compelling For Both Companies & Shareholders Strategic Business Rationale Enables each company to:Tailor business strategies to best address opportunities within its target marketEnhance business focus and better align resources to achieve strategic prioritiesPursue distinct capital structures and
Slide 5: Benefits to Emergent
5 Benefits to Emergent Strategic Business Rationale Establishes Emergent as a “pure play” company, recognized as a leader in the biodefense and emerging infectious diseases fieldsEnhances its financial returns/operating margins Reduces burdens on cash flow associated with oncology R&DEliminates sale
Slide 6: Emergent BioSolutions after the spin-off
6 Management team to remain in place: CEO ∙ Daniel Abdun-NabiCFO ∙ Robert Kramer Comprehensive capabilities Flexible technologiesInspected and approved by regulatory agencies from the US, EU, JapanInternational distribution and sales cGMP ManufacturingFill/Finish CMO Services Lan Hatt Cam Win USA-MI
Slide 7: Enhanced Financial Performance
7 Enhanced Financial Performance Emergent Financial Profile Continued Revenue Growth Organic and M&AProduct salesContracts, grants and collaborationsCMO revenue, including the manufacture of products for SpinCo Enhanced Balance Sheet Allows pursuit of optimal capital deployment opportunitiesTargeted
Slide 8: Benefits to SpinCo
8 Benefits to SpinCo Strategic Business Rationale Establishes SpinCo as a “pure play” biopharmaceutical company in the highly attractive field of immuno-oncologyTargets investments and operations in the development of bi-specific therapeutics using the proprietary ADAPTIR platform technologyEnables
Slide 9: SpinCo Company Profile
9 A biopharmaceutical company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives Company Profile SpinCo Product/Candidate Indication Pre-Clinical Clinical Development Stage Marketed Phase I Phase II Phase III IXINITY Hemophilia B WinRho ITP HepaGam B HBV VA
Slide 10: Technology Core to the Company: SpinCo Immuno-Oncology Platform
10 Technology Core to the Company SpinCo Immuno-Oncology Platform A promising, novel approachfor generation of immuno-therapeutics Suitable for producing immuno-therapeutics for oncology or AIID utilizing different modes of actionRedirected T-cell CytotoxicityTargeted Cytokine Delivery Successful hi
Slide 11: Capitalized to Create Value: SpinCo Financial Profile
11 Fixed cash contribution from Emergent of $50M-$70M R&D investment partially offset by:Growing contribution from IXINITYStable contribution from mature products: WinRho, HepaGam B, VARIZIGFunding from existing MOR209/ES414 partnershipPositioned for future funding to support development programs Ne
Slide 12: Biosciences Business Spin-off Transaction Details
12 Biosciences Business Spin-off Transaction Details Structure Tax-free distribution to Emergent shareholders of common stock of SpinCoStock distribution ratio to be determined Timing Transaction anticipated to be completed in mid-2016 (subject to closing conditions) Naming Corporate name for SpinCo
Slide 13: Biosciences Business Spin-off Summary
13 Biosciences Business Spin-off Summary Spin-off is expected to create two independent public companies with distinct strategic plans, growth strategies, and operational and development priorities Enables Emergent to establish itself as a “pure play” company in the biodefense and emerging infectiou
Slide 14: Biosciences Spin-Off
Biosciences Spin-OffAugust 6, 2015 Daniel J. Abdun-NabiPresident and CEO
Emergent BioSolutions — Merger or Acquisition (August 2015) on 6ix